<DOC>
	<DOCNO>NCT01130805</DOCNO>
	<brief_summary>In order improve survival metastatic gastric cancer patient , plan conduct phase II trial CapeOx 800 mg once-daily pazopanib first-line chemotherapy metastatic gastric cancer patient .</brief_summary>
	<brief_title>A Study Pazopanib With CAPEOX AGC Patients</brief_title>
	<detailed_description>Despite improvement early diagnosis gastric cancer , many patient present inoperable disease effective , novel combination treatment urgently need patient population . A recent meta-analysis demonstrate chemotherapy improves survival patient advance gastric cancer compare best supportive care alone [ hazard ratio ( HR ) 0.39 , 95 % confidence interval ( CI ) 0.28-0.52 ] combination chemotherapy superior monotherapy ( HR 0.83 , 95 % CI 0.74-0.93 ) ( Wagner et al. , 2006 ) . For advanced gastric cancer , 5-FU combination cisplatin ( FP regimen ) commonly use reference regimen , successfully replace capecitabine oxaliplatin recent phase III trial ( Cunningham et al. , 2008 ; Okines et al. , 2009 ) . In phase II trial , CAPEOX ( capecitabine combine oxaliplatin ) regimen also show promising activity metastatic gastric cancer ( Park et al. , 2006 ; Park et al. , 2008 ) . In order improve survival metastatic gastric cancer patient , various clinical trial incorporate novel molecularly target agent combination reference arm .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Subjects provide write informed consent Age 18 year Histologically proven unresectable gastric cancer ECOG performance status 02 At least one unidimensionally measurable lesion RECIST criterion ver 1.1 Adequate organ system function absolute neutrophil count &gt; 1,500/µL , platelet &gt; 100,000/µL , hemoglobin &gt; 9g/dl Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) , AST ALT &lt; 2.5 time ULN , PT ( INR ) , PTT &lt; 1.2 time UNL Serum creatinine le 1.5 mg/dL Calculated Ccr least 50 mL/min , Urine Protein Creatinine Ratio ( UPC ) less 1 female Nonchildbearing potential Prior malignancy History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include Clinically significant gastrointestinal abnormality may affect absorption investigational product Presence uncontrolled infection Corrected QT interval ( QTc ) 480 msec use Bazett 's formula History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting , Myocardial infarction , Unstable angina , Coronary artery bypass graft surgery , Symptomatic peripheral vascular disease , Class II higher congestive heart failure Poorly control hypertension antihypertensive agent History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer Evidence active bleeding bleed diathesis Hemoptysis within 6 week first dose study drug Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure Unable unwilling discontinue use prohibit medication list protocol Treatment follow anticancer therapy ; Radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib ; biologic therapy , immunotherapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib ; No prior chemotherapy except adjuvant chemotherapy ( Patients receive adjuvant chemotherapy least 6 month prior study entry allow regardless chemotherapeutic regimen Preexisting grade 2 ( high ) motor sensory neuropathy CTCAE v4.0 Known allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>gastric cancer pazopanib capecitabine , oxaliplatin</keyword>
	<keyword>Metastatic recurrent gastric cancer</keyword>
</DOC>